An interventional study of Hyivy Intravaginal Device in Endometriosis and Pelvic Pain, sponsored by Hyivy Health Inc. Not yet recruiting at 1 site in Canada. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-09-17.
Sponsored by Hyivy Health Inc · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 34 studies in Endometriosis with a site in Canada — 12 open to participants now, 13 under way, none of them phase 3. Endometriosis · Canada.
Among the 34 studies in Endometriosis with a site in Canada, this one is the 18th largest by planned enrollment of the 23 interventional ones that give a count, is one of 3 that started in 2025, is one of 11 with no phase, reaches primary completion later than 1 of the 12 other live ones, and was the 21st registered.
924 studies on the registry are indexed under Endometriosis; 268 are open to participants now.
Browse Endometriosis studies →12 of the 34 studies in Endometriosis with a site in Canada are open now. Recruiting first, the newest first:
Université de Sherbrooke · Sites in Canada
Ages 18–45 · Women only
Trio Fertility · Sites in Canada
Ages 18–45 · Women only · Healthy volunteers
McGill University Health Centre/Research Institute of the McGill University Health Centre · Sites in Canada
Ages 18+ · Women only · Healthy volunteers
Sunnybrook Health Sciences Centre · Sites in Canada
Ages 18+
Andrew Zakhari · Sites in Canada
Ages 18+ · Women only
A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →
Of the 180 Endometriosis studies recruiting now, 53 (29%) set no upper age limit and 125 (69%) stop at 75 or younger; 18 take children under 18; 39 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
34 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 3 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 20 is below the median of 67 across 542 interventional studies indexed under Endometriosis.
Median enrollment 64 across the 23 interventional studies, 126 across the 11 observational. Of the 19 that completed or were terminated, 9 (47%) have results posted.
This tab as a report to print or save as PDF → With an account.
14 of 34 have an industry lead sponsor. The 10 most frequent:
Hyivy Health Inc is the lead sponsor of 2 studies on the registry; 2 are open to participants now.
Hyivy Health Inc has 1 study filed under Endometriosis — fewer than ten, so there is no comparison to draw.
9 of the studies in Endometriosis with a site in Canada that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05643131Hyivy Health IncHyivy Device as Non-hormonal Therapy in Endometriosis | 2026-12 |
| NCT05523284McMaster UniversityCombining Ultrasound and Biomarkers to Diagnose Superficial Endometriosis | 2026-12-30 |
| NCT07713797Trio FertilityBiomarkers for Endometriosis | 2027-01-01 |
| NCT07731776Université de SherbrookeImproving Access to Pelvic Health Physiotherapy for Endometriosis | 2027-03-29 |
| NCT06472765Vaginal Biome ScienceVaginal Ecosystem and Network in the United States Study | 2027-05-15 |
Add all 9 to your calendar (.ics) → With an account.
Among the 34 studies in Endometriosis with a site in Canada, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study seeks to address accessible management of endometriosis-associated chronic pelvic pain by evaluating a novel device used in the home. The study is designed as a proof-of-concept single-arm pilot study, and the primary objective is to assess change in overall self-reported pelvic pain in people with endometriosis-associated chronic pelvic pain following the use of the Hyivy intravaginal device.
Endometriosis is a chronic, inflammatory, estrogen-dependent disease characterized by ectopic growth of uterine-like cells outside the uterus. People living with endometriosis typically experience debilitating pelvic pain (dysmenorrhea, dyspareunia, dyschezia, dysuria, non-menstrual pelvic pain), and infertility. Endometriosis also has significant negative impacts on quality of life, physical, mental, and social wellbeing.
There is no diagnostic marker nor cure for this chronic disease. Current treatment options include medical therapies (mainly hormonal treatments aimed at suppressing menstruation or growth of the ectopic cells), surgery (to remove endometriotic lesions/nodules), and complementary or alternative therapies (non-medical or surgical options to manage symptoms; heat, mindfulness, diet, yoga, natural remedies, physical therapies, etc.).
Many people living with endometriosis report having used self-management strategies (complementary and alternative therapies) to manage their symptoms, and research on treatments and alternative therapies are consistently ranked among the top endometriosis research priorities. Alternative therapies have the potential to complement existing medical and surgical therapies, offering additional options to manage symptoms like pain.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive a Hyivy intravaginal device for at-home use. Recommended use is three times per week for 12 weeks and consists of 10 minutes of heat (37-39ºC) and 10 minutes of dilation per session.
Device: Hyivy Intravaginal Device
Intravaginal use of Hyivy device three times per week for 12 weeks, with each session consisting of 10 minutes of heat (37-39ºC) and 10 minutes of dilation.
Overall self-reported pelvic pain
Overall pelvic pain will be evaluated using a digital visual analog scale (VAS)
Time frame: Baseline, 6-weeks, 12-weeks
Site-specific tenderness and pelvic floor muscle pain
Site-specific tenderness and pelvic floor muscle pain will be measured by the Biberoglu and Behrman scale (B\&B) ranging from 0 (none) to 15 (severe) and patient exams
Time frame: Baseline, 6-weeks, 12-weeks
Quality of Life (EHP-30)
Changes in quality of life as assessed by the Endometriosis Health Profile-30 (EHP-30) ranging from 0 (best possible health status) to 100 (worst possible health status).
Time frame: Baseline, 6-weeks, 12-weeks
Sexual Function (FSFI)
Changes in sexual function as assessed by the Female Sexual Function Index (FSFI). Scores range from 2 to 36 with higher scores indicating greater functioning.
Time frame: Baseline, 6-weeks, 12-weeks
Safety and tolerability of the Hyivy device
Occurrence of adverse events (AE) and serious adverse events (SAE).
Time frame: Up to 12-weeks
Adherence to study protocol
Usage data collected by the Hyivy device will be used to assess participant adherence to the study regimen of 3 times/week device use.
Time frame: 6-weeks, 12-weeks
Feasibility of the Hyivy device
Device usage will be assessed with a study-specific questionnaire.
Time frame: 6-weeks, 12-weeks
Use of rescue medication
Changes in the use of rescue medications for chronic pelvic pain, assessed with a study-specific questionnaire.
Time frame: Baseline, 6-weeks, 12-weeks
Autonomic function
Autonomic nervous system (ANS) function will be assessed using measures of heart rate variability (HRV) during a deep breathing test, active standing test, and water intake test.
Time frame: Baseline, 6-weeks, 12-weeks
Peripheral gene expression
Changes in peripheral inflammation as assessed by a protein biomarker panel before and after device use
Time frame: Baseline, 6-weeks, 12-weeks
Emergency room (ER) visits
Number of ER visits due to chronic pelvic pain in the last 6 weeks
Time frame: Baseline, 6-weeks, 12-weeks
Device usability and patient satisfaction
Study-specific questionnaire to gather patient feedback
Time frame: 12-weeks
Plan to share: No — There is no plan to make individual participant data available to other researchers.
Start is estimated for Oct 2025; primary completion for Dec 2026, 14 months later.
Of 214 interventional studies with no phase under Endometriosis, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 44. This study's planned 14 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Hyivy Health Inc